At a glance
ClinicalIndex Comparison RecordPhase 2Active· 29 enrolled
Drug / intervention
Peginterferon alfa-2b +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
In Brief
A Phase 2 clinical trial evaluating Peginterferon alfa-2b, Temozolomide, and 1 other intervention for Malignant Melanoma. Active but no longer recruiting, targeting 29 participants across 3 sites.
Detailed Summary
The main goal of this study is to estimate the tumor response rate of temozolomide administered in combination with peginterferon alfa-2b to pediatric patients with unresectable Stage III, metastatic, or recurrent cutaneous melanoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Melanoma
CountriesUnited States
CollaboratorsSchering-Plough
Timeline
Phase 2Active
200820092010201120122013201420152016201720182019202020212022202320242025202620272028202920302031
First PostedOct 2007
Enrollment StartMay 2008
Primary CompletionJun 2015
TodayJul 2026
Study CompletionMay 2031
First PostedOct 4, 2007
Enrollment StartMay 9, 2008
Primary CompletionJun 1, 2015
Study CompletionMay 1, 2031
TodayJul 2, 2026
Enrollment to primary: 7.1 yearsPosted 18.7 years ago
Interventions
Peginterferon alfa-2bdrug
Given either IV or SQ. Therapeutic drug class: interferon.
Temozolomidedrug
Given PO. Therapeutic drug class: antineoplastic agent.
Recombinant interferon alfa-2bdrug
Given IV. Therapeutic drug classes: antineoplastic agent, immunomodulatory agent, interferon